Last 40 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 41.21 | 40.56 | 51.91 | 35.29 | 36.26 | 16.59 | 26.64 | 37.56 | 25.77 | 50.01 | 86.62 | 1482.75 | 103.38 | 10.39 | — | — | — | — | — | — | — |
| — | +144.4% | +94.9% | -6.1% | +40.7% | -66.8% | -69.2% | -97.5% | -75.1% | +381.1% | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 18.87 | 20.13 | 23.89 | 16.93 | 17.24 | 13.46 | 10.64 | 15.27 | 12.84 | 16.23 | 19.36 | 28.79 | 21.21 | 97.93 | — | — | — | — | — | — | — |
| — | +49.6% | +124.5% | +10.9% | +34.2% | -17.1% | -45.0% | -47.0% | -39.5% | -83.4% | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 7.39 | 7.14 | 8.38 | 6.17 | 6.05 | 4.63 | 3.93 | 5.47 | 4.95 | 6.14 | 6.49 | 6.52 | 4.59 | 4.43 | 4.79 | 4.20 | 3.88 | 3.30 | 3.00 | 3.05 | 2.62 |
| — | +54.4% | +113.3% | +12.9% | +22.4% | -24.7% | -39.4% | -16.1% | +7.7% | +38.6% | +35.4% | +55.1% | +18.4% | +34.3% | +59.7% | +38.0% | +48.2% | +16.2% | -16.9% | -19.9% | -36.4% | |
| P/FCF | 28.61 | 28.41 | 39.99 | 26.90 | 24.49 | 34.69 | 20.11 | 54.37 | 22.49 | 23.54 | — | 89.07 | — | — | — | — | — | — | — | — | — |
| — | -18.1% | +98.8% | -50.5% | +8.9% | +47.4% | — | -39.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 35.76 | 33.64 | 45.74 | 33.33 | 37.32 | 28.40 | 22.92 | 33.63 | 25.29 | 52.96 | 120.54 | — | 173.57 | — | — | — | — | — | — | — | — |
| — | +18.5% | +99.6% | -0.9% | +47.6% | -46.4% | -81.0% | — | -85.4% | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 51.97 | 30.57 | 41.52 | 30.06 | 45.56 | 25.45 | 20.02 | 29.17 | 22.34 | 36.33 | 60.58 | 208.93 | 75.65 | — | — | — | — | — | — | — | — |
| — | +20.1% | +107.4% | +3.1% | +103.9% | -29.9% | -67.0% | -86.0% | -70.5% | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.6% | 94.1% | 94.6% | 94.6% | 89.8% | 94.2% | 92.5% | 94.3% | 94.6% | 92.0% | 91.5% | 94.7% | 89.6% | 97.4% | — | — | — | — | — | — | — |
| — | -0.2% | +2.2% | +0.3% | -5.0% | +2.4% | +1.2% | -0.4% | +5.5% | -5.5% | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | 41.5% | 55.9% | 49.0% | 46.1% | 41.5% | 42.3% | 40.9% | 41.0% | 45.4% | 26.8% | 12.2% | -14.8% | 7.4% | -303.8% | — | — | — | — | — | — | — |
| — | +32.1% | +19.7% | +12.5% | -8.6% | +58.1% | +235.8% | +377.7% | +509.7% | +108.8% | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | 52.6% | 49.5% | 45.9% | 48.1% | 48.0% | 81.2% | 39.9% | 40.5% | 49.9% | 32.4% | 22.2% | 2.1% | 20.6% | 943.7% | — | — | — | — | — | — | — |
| — | -39.0% | +15.1% | +18.6% | -3.8% | +150.3% | +80.2% | +1867.3% | +141.9% | -96.6% | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 18.9% | 4.5% | 4.2% | 4.5% | 4.4% | 7.3% | 3.8% | 3.7% | 5.0% | 3.2% | 1.9% | 0.1% | 1.1% | 11.5% | -5.8% | -9.0% | -6.0% | -5.4% | -5.1% | -8.7% | -4.4% |
| — | -38.1% | +9.8% | +21.1% | -12.2% | +131.2% | +99.2% | +3033.7% | +338.2% | -72.5% | +132.7% | +101.3% | +118.8% | +311.2% | -14.5% | -2.3% | -38.5% | -43.9% | -31.7% | -100.0% | -24.5% | |
| ROA | 17.1% | 4.1% | 3.8% | 4.1% | 4.0% | 6.7% | 3.5% | 3.4% | 4.5% | 2.9% | 1.8% | 0.1% | 1.1% | 11.0% | -5.5% | -8.3% | -5.6% | -5.1% | -4.6% | -8.0% | -4.0% |
| — | -38.8% | +9.1% | +22.1% | -10.5% | +133.3% | +97.1% | +2908.8% | +313.0% | -73.9% | +132.2% | +101.3% | +119.1% | +316.1% | -18.4% | -3.4% | -39.5% | -45.5% | -25.0% | -91.6% | -21.3% | |
| ROIC | 18.0% | 5.6% | 5.1% | 5.3% | 4.5% | 4.3% | 4.3% | 4.2% | 5.5% | 3.3% | 1.4% | -1.1% | 0.6% | -5.0% | -7.7% | -10.1% | -7.1% | -6.6% | -6.8% | -6.9% | -8.4% |
| — | +29.9% | +19.1% | +26.6% | -18.5% | +29.6% | +215.1% | +466.5% | +857.9% | +165.7% | +117.6% | +88.6% | +108.1% | +24.1% | -13.6% | -46.2% | +15.4% | +36.2% | +64.5% | +78.3% | +68.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
| — | -28.4% | -30.0% | -27.3% | -0.2% | -0.9% | +1.5% | -0.7% | -26.2% | -23.3% | -29.9% | -44.8% | -39.2% | -34.8% | -19.9% | +5.6% | +26.5% | -15.0% | -12.7% | +88.5% | -65.8% | |
| Debt / EBITDA | 0.06 | 0.12 | 0.15 | 0.16 | 0.20 | 0.22 | 0.24 | 0.26 | 0.17 | 0.31 | 0.73 | — | 1.74 | — | — | — | — | — | — | — | — |
| — | -46.7% | -37.7% | -35.7% | +19.5% | -29.1% | -67.4% | — | -90.3% | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.95 | 7.89 | 8.32 | 9.46 | 9.95 | 10.14 | 9.68 | 9.65 | 7.28 | 7.97 | 9.50 | 12.66 | 17.76 | 21.10 | 20.25 | 10.13 | 13.30 | 14.18 | 12.45 | 7.25 | 17.18 |
| — | -22.2% | -14.1% | -1.9% | +36.8% | +27.3% | +1.9% | -23.8% | -59.0% | -62.3% | -53.1% | +24.9% | +33.5% | +48.8% | +62.6% | +39.8% | -22.6% | +46.7% | -39.0% | -83.7% | -3.5% | |
| Quick Ratio | 9.56 | 7.53 | 7.96 | 9.06 | 9.56 | 9.73 | 9.33 | 9.27 | 7.02 | 7.76 | 9.33 | 12.42 | 17.55 | 20.91 | 20.25 | 10.13 | 13.30 | 14.18 | 12.45 | 7.25 | 17.18 |
| — | -22.6% | -14.6% | -2.2% | +36.3% | +25.4% | -0.1% | -25.4% | -60.0% | -62.9% | -53.9% | +22.6% | +31.9% | +47.5% | +62.6% | +39.8% | -22.6% | +46.7% | -39.0% | -83.7% | -3.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 40 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KRYS stock.
Krystal Biotech, Inc.'s current P/E is 41.2x. The average P/E over the last 4 quarters is 41.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Krystal Biotech, Inc.'s current operating margin is 41.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Krystal Biotech, Inc.'s business trajectory between earnings reports.